Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- TJ Biopharma Co., Ltd.
- Target Recruit Count
- 376
- Registration Number
- NCT04322006
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04284488
- Locations
- 🇨🇳
Sun-Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The Affiliated Hospital OF Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Foshan First People's Hospital, Foshan, Guangdong, China
Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04248387
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Target Recruit Count
- 60
- Registration Number
- NCT04238169
- Locations
- 🇨🇳
Xinqiao Hospital of Chongqing, Chongqing, Chongqing, China
Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 164
- Registration Number
- NCT04229849
Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04177797
- Locations
- 🇨🇳
Sichuan Cancer Hospital and Research Institute, Chengdu, Sichuan, China
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
- Conditions
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 25
- Registration Number
- NCT04170179
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 248
- Registration Number
- NCT04169672
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT
- Conditions
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT04169399
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 90
- Registration Number
- NCT04164238
- Locations
- 🇨🇳
Department of Medical Onocology, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.